I do worry that on the rare occasions BMY (and other CI companies) do get a hit, it's because they have so many trial combos, the winners are by chance.
Then there is a whole bunch of Keytruda trials. Combo'ing up with anything and everything including Optune and an autologous vaccine (HSPPC-95, Agenus I think) and a Car-T.
As with Nivo, nothing that appears anywhere near to an outcome that could lead to an approval.
Then there is a whole bunch of Keytruda trials. Combo'ing up with anything and everything including Optune and an autologous vaccine (HSPPC-95, Agenus I think) and a Car-T.
As with Nivo, nothing that appears anywhere near to an outcome that could lead to an approval.